Molecular Pharmaceutics,
Год журнала:
2024,
Номер
22(1), С. 81 - 102
Опубликована: Ноя. 27, 2024
The
COVID-19
pandemic
has
spotlighted
the
potential
of
in
vitro
transcribed
(IVT)
mRNA
vaccines
with
their
demonstrated
efficacy,
safety,
cost-effectiveness,
and
rapid
manufacturing.
Numerous
IVT
are
now
under
clinical
trials
for
a
range
targets,
including
infectious
diseases,
cancers,
genetic
disorders.
Despite
promise,
face
hurdles
such
as
limited
expression
levels,
nonspecific
targeting
beyond
liver,
degradation,
unintended
immune
activation.
Overcoming
these
challenges
is
crucial
to
harnessing
full
therapeutic
global
health
advancement.
This
review
provides
comprehensive
overview
latest
research
progress
optimization
strategies
molecules
delivery
systems,
application
artificial
intelligence
(AI)
models
deep
learning
techniques
structure
formulation
design.
We
also
discuss
recent
development
platforms,
lipid
nanoparticles
(LNPs),
polymers,
exosomes,
which
aim
address
related
protection,
cellular
uptake,
targeted
delivery.
Lastly,
we
offer
insights
into
future
directions
improving
vaccines,
hope
spur
further
vaccine
development.
Cancers,
Год журнала:
2024,
Номер
16(17), С. 2975 - 2975
Опубликована: Авг. 27, 2024
Malignant
gliomas
present
great
difficulties
in
treatment,
with
little
change
over
the
past
30
years
median
survival
time
of
15
months.
Current
treatment
options
include
surgery,
radiotherapy
(RT),
and
chemotherapy.
New
therapies
aimed
at
suppressing
formation
new
vasculature
(antiangiogenic
treatments)
or
destroying
formed
tumor
(vascular
disrupting
agents)
show
promise.
This
study
summarizes
existing
knowledge
regarding
processes
by
which
glioblastoma
(GBM)
tumors
acquire
resistance
to
antiangiogenic
treatments.
The
discussion
encompasses
activation
redundant
proangiogenic
pathways,
heightened
cell
invasion
metastasis,
induced
hypoxia,
creation
vascular
mimicry
channels,
regulation
immune
microenvironment.
Subsequently,
we
explore
potential
strategies
overcome
this
resistance,
such
as
combining
other
methods,
personalizing
treatments
for
each
patient,
focusing
on
therapeutic
targets,
incorporating
immunotherapy,
utilizing
drug
delivery
systems
based
nanoparticles.
Additionally,
would
like
discuss
limitations
methods
future
directions
enhance
beneficial
effects
patients
GBM.
Therefore,
review
aims
research
outcome
GBM
provide
a
more
promising
opportunity
thoroughly
exploring
mechanisms
investigating
novel
strategies.
Biomarker Research,
Год журнала:
2024,
Номер
12(1)
Опубликована: Ноя. 13, 2024
Lung
cancer
leads
in
causing
cancer-related
mortality
worldwide,
continually
posing
a
significant
threat
to
human
health.
Current
imaging
diagnostic
techniques,
while
offering
non-invasive
detection,
suffer
from
issues
such
as
insufficient
sensitivity
and
the
risks
associated
with
radiation
exposure.
Pathological
diagnosis,
gold
standard
for
confirmation,
also
faces
challenges
like
invasiveness
high
costs.
In
treatment,
surgery,
radiotherapy,
chemotherapy
are
main
modalities,
each
encountering
related
precision,
environmental
adaptability,
side
effects.
Nanotechnology's
advancement
provides
new
solutions
diagnosis
treatment
of
lung
cancer,
promising
enhance
accuracy
reduce
effects
during
treatment.
This
article
introduces
types
nanomaterials
used
field
comprehensive
overview
current
research
on
application
nanotechnology
early
screening,
monitoring
summarizing
ongoing
clinical
findings.
Signal Transduction and Targeted Therapy,
Год журнала:
2024,
Номер
9(1)
Опубликована: Ноя. 14, 2024
Abstract
In
the
last
decade,
messenger
ribonucleic
acid
(mRNA)-based
drugs
have
gained
great
interest
in
both
immunotherapy
and
non-immunogenic
applications.
This
surge
can
be
largely
attributed
to
demonstration
of
distinct
advantages
offered
by
various
mRNA
molecules,
alongside
rapid
advancements
nucleic
delivery
systems.
It
is
noteworthy
that
immunogenicity
presents
a
double-edged
sword.
context
immunotherapy,
extra
supplementation
adjuvant
generally
required
for
induction
robust
immune
responses.
Conversely,
non-immunotherapeutic
scenarios,
activation
unwanted
considering
host
tolerability
high
expression
demand
mRNA-encoded
functional
proteins.
Herein,
mainly
focused
on
linear
non-replicating
mRNA,
we
overview
preclinical
clinical
progress
prospects
medicines
encompassing
vaccines
other
therapeutics.
We
also
highlight
importance
focusing
host-specific
variations,
including
age,
gender,
pathological
condition,
concurrent
medication
individual
patient,
maximized
efficacy
safety
upon
administration.
Furthermore,
deliberate
potential
challenges
may
encounter
realm
disease
treatment,
current
endeavors
improvement,
as
well
application
future
advancements.
Overall,
this
review
aims
present
comprehensive
understanding
mRNA-based
therapies
while
illuminating
prospective
development
drugs.
ACS Nano,
Год журнала:
2024,
Номер
18(17), С. 11335 - 11348
Опубликована: Апрель 15, 2024
Leveraging
the
extensive
surface
area
of
lungs
for
gene
therapy,
inhalation
route
offers
distinct
advantages
delivery.
Clinical
nebulizers
that
employ
vibrating
mesh
technology
are
standard
choice
converting
liquid
medicines
into
aerosols.
However,
they
have
limitations
when
it
comes
to
delivering
mRNA
through
inhalation,
including
severe
damage
nanoparticles
due
shearing
forces.
Here,
we
introduce
a
microfluidic
aerosolization
platform
(MAP)
preserves
structural
and
physicochemical
integrity
lipid
nanoparticles,
enabling
safe
efficient
delivery
respiratory
system.
Our
results
demonstrated
superiority
MAP
over
conventional
nebulizer,
as
avoided
problems
such
particle
aggregation,
loss
encapsulation,
deformation
nanoparticle
morphology.
Notably,
aerosolized
generated
by
device
led
enhanced
transfection
efficiency
across
various
cell
lines.
In
vivo
experiments
with
mice
inhaled
these
revealed
successful
lung-specific
without
observable
signs
toxicity.
This
may
represent
an
advancement
pulmonary
precise
effective
nanoparticles.
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology,
Год журнала:
2025,
Номер
17(1)
Опубликована: Янв. 1, 2025
ABSTRACT
mRNA
delivery
has
emerged
as
a
transformative
approach
in
biotechnology
and
medicine,
offering
versatile
platform
for
the
development
of
novel
therapeutics.
Unlike
traditional
small
molecule
drugs
or
protein‐based
biologics,
therapeutics
have
unique
ability
to
direct
cells
generate
therapeutic
proteins,
allowing
precise
modulation
biological
processes.
The
into
target
is
critical
step
realizing
potential
this
technology.
In
review,
our
focus
on
latest
advancements
designing
functional
polymers
achieve
efficient
delivery.
Biodegradable
low
molecular
weight
addressing
balance
binding
release
are
summarized.
Benefiting
from
excellent
performance
lipid
nanoparticles
delivery,
polymer/lipid
hybrid
nanostructures
also
included.
Finally,
challenges
future
prospects
polymer‐based
systems
discussed.
Biomacromolecules,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 23, 2025
Engineered
natural
killer
(NK)
cells
eliminate
cancer
by
overexpressing
a
chimeric
antigen
receptor,
producing
highly
efficient
and
safe
NK
cell
therapies.
This
study
investigated
the
polyplex
formulation
for
fusion
protein
GreenLantern-natural
group
2D
(NKG2D)
mRNA
to
evaluate
its
ex
vivo
delivery
efficacy
into
cells,
wherein
NKG2D
on
surface
of
recognized
counterpart
ligands
cells.
Amphiphilic
polyaspartamide
derivatives
Chol-PAsp(DET/CHE)
were
prepared
adding
cyclohexylethylamine
(CHE)
diethylenetriamine
(DET)
in
side
chains
cholesterol
(Chol)
at
α-terminus
enhance
endosomal
escapability
optimize
hydrophobicity.
significantly
improved
NK-92mi
explained
increased
stability
cellular
uptake
mRNA.
The
NKG2D-overexpressing
exhibited
high
anticancer
against
human
colon
without
affecting
viability
fibroblasts.
Therefore,
could
be
promising
carrier
engineering
Molecular Pharmaceutics,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 25, 2025
Ribonucleic
acid
(RNA)-based
therapies
represent
a
promising
class
of
drugs
for
the
treatment
non-small
cell
lung
cancer
(NSCLC)
due
to
their
ability
modulate
gene
expression.
Therapies
leveraging
small
interfering
RNA
(siRNA),
messenger
(mRNA),
microRNA
(miRNA),
and
antisense
oligonucleotides
(ASOs)
offer
various
advantages
over
conventional
treatments,
including
target
specific
genetic
mutations
potential
personalized
medicine
approaches.
However,
clinical
translation
these
therapeutics
NSCLC
faces
challenges
in
delivery
immunogenicity,
negative
charge,
large
size,
which
can
be
mitigated
with
platforms.
In
this
review,
we
provide
description
pathophysiology
an
overview
RNA-based
therapeutics,
specifically
highlighting
application
NSCLC.
We
discuss
relevant
classes
therapeutic
then
non-viral
strategies
such
as
lipid-
polymer-based
nanoparticles
that
have
been
developed
address
issues
preclinical
models.
Furthermore,
summary
table
trials
leverage
[which
includes
National
Clinical
Trial
(NCT)
numbers]
highlight
current
progress
also
how
integrated
existing
modalities
enhance
efficacy
improve
patient
outcomes.
Overall,
aim
tackle
while
showcasing
RNA's
next-generation
therapy
treatment.
